Trial Profile
A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary) ; Linezolid; Piperacillin/tazobactam
- Indications Bacterial infections; Nosocomial pneumonia; Ventilator associated pneumonia
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme Corp.
- 19 Jul 2022 Status changed from active, no longer recruiting to completed.
- 26 Jun 2022 Planned End Date changed from 31 Oct 2022 to 31 Jul 2022.
- 26 Jun 2022 Planned primary completion date changed from 31 Oct 2022 to 31 Jul 2022.